Please read Dr. Lechner’s article titled, “COVID-19 Pandemic Response Varies by Clinical Trial Sponsor Type.“
The conclusion of 2020 marked nearly 82 million globally confirmed cases of COVID-19, the respiratory disease caused by the novel coronavirus, SARS-CoV-2 (or 2019-nCov). The disease, which was initially identified in Wuhan, China in December 2019, was declared a global pandemic by the World Health Organization (WHO) on March 22, 2020 and quickly spread throughout the world. The virus is spread from person to person via respiratory droplets, with symptoms of disease ranging from asymptomatic to critical. It is believed that underlying genetic predisposition and co-morbidities, including advanced age, play a significant role in disease severity. Initial treatment of COVID-19 infected patients focused on reducing symptoms and providing supportive care. As the number of cases exponentially grew, the anticipated strain on healthcare resources, such as ICU beds, personal protective equipment (PPE), ventilators, and even healthcare personnel, resulted in the establishment of strict business, travel, and community guidelines by the Center of Disease Control (CDC), designed to slow the spread of disease. To read the full article.
COVID-19 Pandemic Response Varies by Clinical Trial Sponsor Type. Cooper L, Lee I, Lechner DW. Published online by Cambridge University Press: 16 March 2021, pp. 1-20